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Certificates of analysis: a challenge 
to interpret
Abstract
The active pharmaceutical ingredient (API) in a medicinal product is the component that is 
responsible for the therapeutic effect. The personnel at the ANSES Fougères Laboratory routi-
nely handle medicinal analytical standard and calculate their API content using the certificates 
of analysis provided by the manufacturer. However, meaningful data in these documents are 
not always easy to determine or may sometimes be absent: interpretation of these data can 
therefore result in assessment errors. Having identified this problem, the ANSES Laboratory 
has put forward an approach aimed at harmonising interpretation of certificates of analysis.
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Introduction
Medicinal products, both for human and veterinary use, contain a single drug substance or 
multiple drug substances, and excipients. The drug substance (DS), or active pharmaceutical 
ingredient (API), is the compound that underlies the pharmacological and therapeutic effects.
Given the various national and European mandates of the ANSES Fougères Laboratory as 
a reference laboratory in the area of veterinary medicinal products, its personnel handle me-
dicinal analytical standards on a daily basis. This work is done as part of testing carried out 
during the development and validation of methods, official controls, proficiency testing, and 
research projects. It is therefore essential for the personnel to be able to calculate the amount 
of API in the analytical standards on the basis of the certificates of analysis (CoAs) supplied 
by the manufacturers.
However, CoAs are not all formulated in the same way and may be incomplete: interpretation 
of data may therefore lead to errors in evaluation.
The ANSES Fougères Laboratory has identified this problem and is therefore putting forward 
an approach to harmonise the interpretation of CoAs.
Certificates of analysis: essential but potentially  
problematic documents
The CoA is a document that defines the analytical standards (name, CAS number, molecular 
formula, molecular weight, etc.) and indicates the required specifications, including appea-
rance, purity, solubility, and water content. It provides the results of the identification and 
quality testing performed by the manufacturer for a batch, on the basis of the criteria cited in 
a pharmacopoeia. Therefore, the CoA is an essential document for any user of an analytical 
standard to determine the API content.
There is, however, no standard certificate of analysis: each manufacturer presents the speci-
fications of the analytical standard and the analytical results on the basis of their own criteria. 
It may happen that important indications for the calculation of the API content are missing or 
imprecise or, more rarely, incorrect. Interpreting CoAs may thus be a sensitive task, potentially 
leading to assessment errors by the operators, especially if the operator is not a chemist by 
initial training.
As an example, the ANSES Fougères Laboratory carried out a survey among two groups of 
operators regularly using antibiotics to test the interpretation of various “critical” CoAs, with 
the users asked to determine the API content in the sample analytical standards. The first 
group was made up of 14 users from a single laboratory (1 CoA for ampicillin sodium), the 
second included 23 users mostly working in different laboratories (3 different CoAs). In both 
cases, the conclusion was clear: whenever there were doubts on interpreting the CoA, or if 
the chemical substance was somewhat complex, the results of API content calculations were 
highly heterogeneous. For instance, in the first group of 14 users, 8 different values were ob-
tained, from 873 to 939 µg ampicillin/mg of ampicillin sodium. For the second group of users, 
the variability of results was of greater concern, specifically for the values obtained from data 
in the CoA for spectinomycin dihydrochloride pentahydrate, where the API content values 
ranged from 363 to 878 µg API/mg of analytical standard.
These tests show unequivocally that there is a paradox in ensuring careful metrological over-
sight of measurement methods if we are less rigorous downstream.
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From the medicinal analytical standard to the active phar-
maceutical ingredient content
The medicinal analytical standard is a powder containing a chemical substance, impurities, 
and often residual water. Indications in the CoA concerning the purity and the residual water 
content of the analytical standard can be used to calculate the chemical substance content. 
The indications concerning the identification of the chemical substance will be used to calcu-
late the API content.
When the CoA is incomplete, calculating the API content of each analytical standard requires 
reference documentary resources that must be made available to the user.
These documents include, on the one hand, pharmacopoeias: they contain various mono-
graphs that indicate the criteria for purity of analytical standards and the analytical methods to 
use for testing purposes. These monographs are authoritative references for any substance 
or formula included in the pharmacopoeia. They provide a recognised framework and are 
regularly updated. On the other hand, the Merck Index has been a reference source for che-
mical products for more than 100 years and presents more than 10,000 monographs, inclu-
ding those for medicinal chemical substances. Testers can consult this Index to supplement 
the information indicated in the CoA when the available pharmacopoeias are not sufficient. 
Likewise, there are several databases for chemical compounds on the internet that are easily 
accessible and comprehensive.
Since difficulties in interpreting CoAs are found repeatedly, but almost never addressed in 
the literature (Brown, 2008), the ANSES Fougères Laboratory decided to take a pragmatic 
approach and create a guide for the interpretation of CoAs, within the framework of the labo-
ratory’s quality assurance system. This approach is described below, step by step.
Content of chemical substance in the analytical standard: 
selecting the value to use
In order to determine the chemical substance content of their analytical standards, manufac-
turers carry out an assay by referring to a reference standard. The results of this testing are 
expressed in the CoA in different ways: either in international units/mg (IU/mg), µg/mg, µg/ml, 
or as a percentage.
On CoAs, some analytical standards with antibiotic activity still have their content expressed 
in IU/mg (bacitracin, colistin, penicillins, sometimes streptomycin and tylosin, etc.), but it is not 
always easy, specifically for chemist users, to understand the notion of conversion coefficients 
IU/mg (originating from WHO standards). At the ANSES Fougères Laboratory, where most 
testing is performed in the framework of reference activities on veterinary medicinal product 
residues, the data of interest are related to the maximum residue limits (MRLs) and are there-
fore expressed in µg/kg. It was therefore decided within this context, excluding microbiological 
testing, that since CoAs for these antibiotics never indicate the level of impurities, this level 
would be considered to be equal to 0%, and therefore that the chemical substance content of 
the analytical standard is equal to 100%. 
If, on the basis of the CoAs, the only quantitative indication that can be used to determine the 
chemical substance content of the analytical standard is purity, expressed in %, we need to 
assimilate this value to a chemical substance content in the analytical standard by default. 
For example, a CoA for cefquinome sulphate indicates: "Purity (HPLC): 99.4%". This figure 
indicates that the batch of analytical standard has a purity of 99.4% in cefquinome sulphate, 
i.e. 994 µg of cefquinome sulphate/mg of analytical standard.
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When the manufacturer indicates on the CoA a value in µg/mg, this complicates matters. In 
general, this value represents the content in API and not the content in chemical substance. 
To be sure, we need to check this information in a pharmacopoeia. In this example of a CoA 
for amikacin sulphate, it is the API content that is indicated: "Potency: 776 µg amikacin base/
mg (anhydrous basis)". When we check the data in the United States Pharmacopoeia (USP), 
we find that the result of the assay must be between 691 and 806 µg amikacin/mg. There-
fore, the value indicated clearly corresponds to the content in amikacin and not in amikacin 
sulphate.
More rarely, a value expressed in µg/mg can reflect the chemical substance content. This is 
the case for tetracycline HCl, for example, since it is always mixed with its epimer, 4-epi-te-
tracycline. Checking in the USP shows that the content in tetracycline HCl, without taking into 
account the epimer, must not be less than 900 µg/mg. 
On some CoAs, the chemical substance content is associated with the expression "as is". 
This means that the manufacturer assayed the chemical substance content in the analytical 
standard as it will be presented in its final packaging, without transformation (specifically loss 
on drying). As a result, the content indicated is the value that must be retained. We must not 
consider the water content of the analytical standard, even if this value is indicated elsewhere.
Some analytical standards are supplied in solution. In most cases, to prepare the solution, 
the supplier took into account the chemical substance content of the analytical standard; the 
chemical substance content of the solution is therefore 100%.
Sometimes, however, a CoA may indicate two values. It then becomes essential to refer to 
the pharmacopoeia to find out whether this is a value for chemical substance content or API 
content. An example from a CoA for ampicillin sodium shows the rationale to follow: "Assay 
(HPLC Weight%): 93.3% - Potency: 878 µg ampicillin/mg": 93.3% represents the % of ampi-
cillin sodium (or chemical substance) in the analytical standard, 878 µg represents the API 
content (ampicillin) in the analytical standard (after verification in the USP35: from 845 to 988 
µg ampicillin/mg). It is easier to retain directly the API content, i.e. the value 878 µg/mg.
If a CoA indicates two values for content expressed in the same way (i.e. both in % or both 
in µg/mg), we should always opt for the value obtained with the most specific method. If, for 
example, we can choose between a value obtained using a titrimetric method and a value 
obtained using a chromatographic method, the second value should be selected.
Understanding the water content of the analytical standard
On the CoAs, manufacturers mostly indicate the water content in analytical standard.
During the manufacturing process of an analytical standard, the chemical substance may be 
combined with one or more H2O molecules or water of crystallisation. A molecule associated 
with water of crystallisation is known by the name hydrate: monohydrate, dihydrate, etc. This 
phenomenon is common, particularly during crystallisation of carboxylic acids and molecules 
presenting in this form such as beta-lactams (penicillins, cephalosporins, carbapenems), 
quinolones and fluoroquinolones.
Various methods (thermogravimetric, chemical, spectrometric) can be used to determine the 
water content. The Karl Fischer (KF) method is a titration technique which is based upon the 
oxidation of sulphur dioxide by iodine in a methanolic hydroxide solution. The KF method 
assays both residual water in the analytical standard (moisture) and water of crystallisation. 
When the method to determine the water content of an analytical standard in the form of 
hydrate (cephalexin hydrate, for example) is the KF method, we must be careful not to take 
into account the H2O molecule when calculating the API/chemical substance ratio. The loss 
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on drying method (gravimetry) is only used to assay residual water in the analytical standard.
On CoAs, water content is indicated but the method that was used to calculate this value is 
not given. For instance, we may see "Water": in most cases, we can find the method used in 
the pharmacopoeia. However, if this is not the case, we should choose the "residual water" 
option, unless we have the CoA for another batch of the analytical standard from the same 
manufacturer, with a similar water content.
In general, the water content is expressed in %, but in some cases it is expressed in mole of 
water/mole of chemical substance: we then need to think in terms of molecular weight. For 
example, the CoA of a batch of apramycin sulphate shows that there are 0.3 moles of water 
per mole of apramycin sulphate. This way of indicating the water content does not simplify the 
calculations. Particularly since, in this case, the sulphate content is also expressed in mole/
mole.
In short, it is essential to know which technique was used to determine the water content. 
To do this, it is very important to refer to the pharmacopoeias. This is particularly critical for 
chemical substances in the form of hydrates.
Identification of the chemical substance: uncertainties
Knowing the identity of the chemical substance will serve to calculate its content in active 
pharmaceutical ingredient (API).
The identity of a chemical substance is indicated in part by its name but it is chiefly determined 
by a unique registration number from the Chemical Abstracts Service (CAS) database. The 
CAS attributes these numbers to all chemical products that have been described in scientific 
documentation. About 30 million compounds have been attributed a CAS number to date.
Most CoAs indicate this CAS number but in some cases it is not given. This can pose a pro-
blem in the event that a chemical substance described has different names. For example, 
cloxacillin sodium is also cloxacillin sodium monohydrate (CAS Number: 7081-44-9), not to 
be confused with cloxacillin sodium which is implied but not indicated as being "anhydrous" 
(CAS Number: 642-78-4). Other examples include pyrantel pamoate and pyrantel embonate, 
which are the same chemical substance (CAS Number: 22204-24-6), as well as sulphame-
thazine, sulphadimidine and sulfadimerazine (CAS Number: 57-68-1). There are many similar 
examples showing the importance of knowing the CAS number. A chemical substance is also 
defined by its formula, whether semi-structural or molecular, and its molecular weight.
All these characteristics can be used to determine whether a chemical substance is a hydrate, 
and whether it is in salt form. The semi-structural formula tells us about the precise structure 
of the molecule, and the number of ions or elements it is made up of, which is not clear solely 
on the basis of the chemical substance’s name. For instance oxytetracycline hydrochloride 
is made up of 1 "oxytetracycline" and 1 "hydrochloride", sisomicin sulphate is 2 "sisomycins" 
and 5 "sulphates", malachite green, 1 "malachite green cation" and 1 "chloride anion". Here 
again, there are multiple examples.
The active pharmaceutical ingredient content in the analyti-
cal standard: some complexity
Once the chemical substance and its chemical structure have been identified, it is easy to 
calculate the active pharmaceutical ingredient:chemical substance ratio (API:CS ratio). For 
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example, for the chemical substance trimethoprim, there is 100% trimethoprim; for emamectin 
benzoate, all we need is the ratio of the molecular weight of emamectin versus that of ema-
mectin benzoate. This yields a content: in this case 86.2%.
However, we will not need a calculation if the CoA indicates the chemical substance content 
of the analytical standard in µg/mg (excluding exceptions, see above). The calculation will 
nonetheless be more complex if the sulphate content is expressed in mole/mole.
We must always exercise caution when dealing with chemical substances that are in ionic 
form. For instance, in the case of nafcillin sodium, nafcillin "base" has lost an H+ proton but 
gained an Na+ proton. Therefore, the difference in molecular weight of nafcillin sodium versus 
nafcillin "base" is 22 instead of 23, a change we need to take account of when calculating the 
nafcillin/nafcillin sodium ratio.
Likewise, we must be careful concerning CoAs for chemical substances in hydrate form, 
where the water content was calculated using the KF method: we must not take the H2O mo-
lecules into account in duplicate.
Once we have determined the purity (or content of the analytical standard in chemical subs-
tance), the water content and the API content (if necessary), these data are multiplied with 
one other to obtain the API content of the analytical standard. This operation is of course to be 
repeated with each change of manufactured batch of the analytical standard.
Example of calculating the API content based  
on the certificate of analysis
FIGURE 1/ Certificate of analysis for a batch of apramycin sulphate
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The CoA used as an example (Figure 1) is for a batch of apramycin sulphate. The CoA is 
complete, but we must note that the molecular weight indicated is that of apramycin and not 
that of apramycin sulphate, which is important for the subsequent calculation.
Also, the CoA indicated that the purity of the analytical standard is equal to 99%, and that the 
water content is equal to 0.3 mole/mole (i.e. of apramycin sulphate) and its sulphate content 
2 moles/mole (of apramycin sulphate).
Firstly, we need to calculate the water content of the analytical standard, expressed as a 
percentage. We must work with the molecular weight because the result is expressed in 
moles:
We then need a formula to obtain the API:CS ratio (active pharmaceutical ingredient:chemical 
substance ratio), also expressed as a percent (%):
As explained above, the data obtained are multiplied by one another to reach the API content 
of the analytical standard:
The API content of the analytical standard is equal to 72.04%, i.e. 720.4 µg active apramycin 
per mg of analytical standard.
The choice of the ANSES Fougères Laboratory:  
centralisation of calculations
To counter the risk of errors when interpreting CoAs, the ANSES Fougères Laboratory opted 
for a centralised approach: all the API contents of medicinal analytical standards used at the 
laboratory are evaluated by a reference person, assisted by deputies. When a CoA is re-
ceived, and using a specific Excel spreadsheet and an internal interpretation guide for CoAs, 
which is constantly updated, the reference person carries out the necessary calculations. This 
person then records the API content of the analytical standard in the Laboratory Information 
Management System (LIMS) as a unique and traceable value that is accessible to all users of 
the analytical standard. The deputies, who are trained in performing these calculations, check 
the data and the record in succession, which also has the effect of ensuring that their skills 
are maintained.
Conclusion
The CoA is an essential document for users of medicinal analytical standards because it 
contains key data to calculate the API content. However, these data are not always easy to 
determine and/or interpret: sometimes, they may be missing or imprecise. To avoid errors in 
interpretation, which are possible among different users, the ANSES Fougères Laboratory 
recommends a standardised approach with data processing referred only to trained personnel 
who can consult a guide on the interpretation of CoAs. In this way, for each batch of medicinal 
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5.4 
741.14
(0.3 mole water (18.01 × 0.3 = 5.4) 
1 mole apramycin (539.58) + 2 moles sulfate (2 × 98.08 = 196.16) + 0.3 mole water (5.4) = = 0.73%
539.58 
735.74
1 mole apramycin (539.58) 
1 mole apramycin (539,58) + 2 moles sulfate (2×98.08=196.16) = = 73.3%
API 
CS
99% (purity)×99.27% (100%-0.73% water)×73.3% (ratio     )=72.04%
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analytical standard, a single value for API content that is verified and traceable is available to 
all laboratory personnel.
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